1. Introduction {#sec1}
===============

1.1. Dengue Virus and Dengue Fever {#sec1.1}
----------------------------------

Dengue virus (DENV), an arthropod-borne human pathogen that can infect people through a mosquito vector (*Aedes aegypti* or *A. albopictus*), has four serotypes (*i.e.* DENV1--4) and is of the genus *Flavivirus*, a member of the family *Flaviviridae* \[[@r1]\]. The global distribution and incidence of DENV infection have increased considerably over recent decades. The World Health Organization (WHO) estimated that 390 million dengue infections occur each year (95% credible interval 284--528 million), of which 96 million (67--136 million) cases manifest clinically at any level of severity \[[@r2], [@r3]\]. A previous study used a systemic analysis to estimate the global prevalence and economic burden of DENV, revealing that approximately 5840 million symptomatic DENV infections in 141 countries resulted in annual global cost US\$8.9 billion \[[@r4]\]. Moreover, according to the previous report containing a systemic review and meta-analysis, the odds ratio of dengue fever incidence increased rapidly from 22 °C to 29 °C, indicating that the risk of in DENV infection is significantly associated with temperature change \[[@r5]\]. In other words, approximately 50% of the world's population is at risk, even with practical preventive strategies such as vector control programs and public health policies \[[@r6]-[@r9]\]. Moreover, the present situation has worsened since the newly genetic variant serotype (DENV-5) was discovered in Southeast Asia and identified in October 2013. This situation has made the development of therapeutics and vaccine for DENV into priority, while complicating vector control and dengue surveillance measures \[[@r10]-[@r12]\]. The world's first approved vaccine trial, Dengvaxia®, developed by Sanofi Pasteur, has recently been shown to lead to severe disease following vaccination and subsequent DENV infection. \[<https://www.nytimes.com/2017/12/17/health/sanofi-dengue-vaccine-philippines.html>\]. Therefore, the Philippines suspended its large-scale dengue vaccination effort, and Sanofi releasing an updated recommends that people who have never been infected with any strain of dengue not to be vaccinated.

Dengue fever has an incubation period of 3--7 days, and is clinically characterized by fever, chills, muscle pain, frontal headache, retro-orbital pain, arthralgia, nausea, and vomiting \[[@r13]\]. A skin rash often presents on the third or fourth day of fever, and its typical cutaneous feature may begin on the extremities or the trunk and spread to other areas including the face. Severe DENV infection can progress to dengue hemorrhagic fever or dengue shock syndrome, which is characterized by hemorrhage and plasma leakage. This life-threatening complication can lead to shock or death in patients who have had a dengue infection episode and are subsequently infected by a different serotype \[[@r14], [@r15]\]; this phenomenon is thought to be caused by antibody-dependent enhancement \[[@r16]-[@r19]\]. Several reports on the various clinical manifestations of dengue infection in several endemic countries have indicated that ocular complication, oral lesions, cardiovascular impairment, and hepatic injury may be involved in the progression of dengue fever \[[@r20]-[@r22]\]. The presence of the DENV-5 serotype could have critical implications for human health and complicate the development of effective therapeutics and vaccines.

1.2. Search Strategy and Selection Criteria {#sec1.2}
-------------------------------------------

References of this review were selected through searches of PubMed for articles published from May 1, 1991 to Oct 1, 2016, with the terms "dengue fever", "dengue virus", "peptide drug", "peptide vaccine", "antimicrobial peptides", "antiviral peptides", "antiviral drug", "immunomodulation", "antidengue strategy". We also search Antimicrobial Peptide Database (APD, <http://aps.unmc.edu/AP/main.php>) and animal model trials documented for relevant antiviral research. Publications from searches of websites released patented drugs are included. Selected review articles are cited to provide readers with more details and references than this review can accommodate.

1.3. Structure and Lifecycle of Dengue Virus {#sec1.3}
--------------------------------------------

To design a vaccine or antiviral drug, the virological structure and lifecycle of DENV must first be understood \[[@r23], [@r24]\]. Similar to other flaviviruses, DENV has an approximately 11-kb positive single-stranded RNA genome encoding a single polyprotein that is processed into three structural proteins, namely capsid (C), premembrane (prM), and envelope (E) glycoproteins, and seven nonstructural proteins (*i.e.* NS1, NS2A/B, NS3, NS4A/B, and NS5) that are crucial for viral propagation \[[@r25], [@r26]\]. Specifically, the structural proteins are responsible for viral particle assembly and budding, and the nonstructural proteins participate in replication of viral genomic RNA \[[@r27]-[@r30]\]. Antidengue strategies are mainly aimed at targeting replication proteins with enzymatic functions, such as NS2B/NS3 (protease), NS3 (helicase), and NS5 (RNA-dependent RNA polymerase, RdRp) \[[@r31], [@r32]\].

Under the present understanding of the molecular structure and lifecycle of DENV, several antidengue strategies have targeted specific steps of key components of the viral life cycle. The main anti-DENV infection strategies are i) activating relevant immune cells of host defense system through vaccines designed using various methods; ii) interfering with the interaction between DENV and host cell receptors or interrupting membranous fusion, which is necessary for infection to occur through the E protein; and iii) interfering with viral replication or recruitment of the viral components necessary for propagation through NS2B/NS3 and NS5 proteins (Fig. **[1](#F1){ref-type="fig"}**) \[[@r31], [@r33]-[@r35]\].

1.4. Antimicrobial and Antiviral Peptides {#sec1.4}
-----------------------------------------

Antimicrobial peptides (AMPs) are a heterogeneous group of primeval molecules comprising highly conserved components found in various living organisms ranging from prokaryotes to humans \[[@r36]-[@r38]\]. Generally, AMPs can be defined as relatively small (6--100 amino acids) and positively charged amphipathic molecules with varying amino acid sequences and lengths according to their biochemical characteristics \[[@r37], [@r39]\]. AMPs play multifunctional roles in the innate immune defense system of mammals, including their capability to directly kill microbes, suppress microbial growth, and stimulate various immune cells \[[@r39]-[@r46]\]. AMPs are promising treatment options because of their broad antimicrobial spectrum against microorganisms such as bacteria, fungi, protozoa, and viruses; furthermore, they have been classified into four major groups according to their secondary structure (*i.e.* α-helical, β-sheet, loop and extended peptides) \[[@r47]-[@r52]\]. More than 2500 AMPs have been documented or predicted in various organisms, and are available through the Antimicrobial Peptide Database (APD, <http://aps.unmc.edu/AP/main.php>). In this database, groups of promising peptides are classified as antiviral peptides (AVPs). There are more than 150 AVPs, including over 90 peptides with anti-HIV features. Because of the importance of antiviral drug discovery, an AVP web server was established to predict highly effective AVPs to assist in developing AVP drugs \[[@r53]\]. The extraordinary properties of AVPs and AMPs demonstrate the following advantages: i) resistance is less likely compared to conventional antibiotics because of the highly diverse and abundant AVPs and AMPs produced by multicellular organisms; ii) the membrane-disturbing activity of AVPs/AMPs is difficult for microbes to evade while maintaining functional cellular membrane and structural integrity; and iii) degradation toward AVPs and AMPs is difficult because microbes would require a designer protease to destroy AVPs and AMPs without devastating host proteins that are necessary for attachment or pathogenic proteins that are essential in the virus lifecycle \[[@r36], [@r54]-[@r57]\].

Regarding AVPs, human defensins demonstrate viral antagonist activities by blocking virus entry to neutralize pathogens such as herpes simplex virus (HSV) and influenza A virus \[[@r58], [@r59]\]. The α- and θ- defensins exhibit extraordinary anti-HIV potential by interacting with receptors on a host cell to oppose viral attachment or entry \[[@r60], [@r61]\]. Because the skin is the first line of immune defense, several well-characterized AVPs are produced by skin-residing cells, such as cathelicidin and β-defensin, for defeating most viral infections and microbial invasions through mucosa or cutaneous tissue \[[@r62]\].

Many studies have focused on discovering novel drugs and vaccine candidates for treating DENV \[[@r23], [@r28], [@r33], [@r35], [@r63]-[@r104]\]. We listed the most widely adopted approaches already mentioned in other reviews, such as immunomodulation, anti-DENV entry, and anti-DENV replication (Table **[1](#T1){ref-type="table"}**) \[[@r23], [@r105]-[@r116]\]. Among these articles, one recommended publication "Peptides as Therapeutic Agents for Dengue Virus" released by Chew *et al.* in 2017 documents and cites all therapeutic peptides from current literature \[[@r117]\]. Before Dengvaxia®, the first dengue vaccine to be licensed, despite the considerable effort toward mitigating the growing threat of a DENV epidemic in the tropical zone, no effective therapeutic agent or licensed vaccine had been developed to prevent DENV infection or treat dengue fever \[[@r2], [@r10], [@r23], [@r28], [@r33], [@r35], [@r65], [@r67], [@r70]-[@r73], [@r76]-[@r99], [@r102], [@r105]-[@r116], [@r118]-[@r132]\]. Bioactive peptides isolated from human tissue or body fluid have been excavated from peptide libraries in order to design inhibitors against HIV-1 infection \[[@r133]\]. Human cathelicidin LL-37 derived from host defense peptides was demonstrated to show protective effect against pulmonary respiratory syncytial virus (RSV) infection in murine model \[[@r134]\]. The potential of peptide libraries offers scientists insight into developing immunomodulatory therapeutic agents and additional antiviral or antimicrobial candidates. Despite the number of high-quality reviews that have been published, only a few of them have specifically highlighted the group of peptide drugs that are among the most promising antidengue strategies to date. In the present review, we focus on discussion as follow: i) categorize one feasible antidengue strategy based on DENV lifecycle; ii) peptides with certain bioactive epitopes having potential served as vaccination candidates; iii) the most effective and promising therapeutic peptides against DENV targeting specific antigenic domain; and iv) the drug discovery potential employing Antimicrobial Peptide Database (APD) to overcome emerging antimicrobial drug resistance.

2. Strategies to Develop antidengue peptide vaccines and drugs {#sec2}
==============================================================

2.1. Development of Peptide Vaccine for Dengue Virus in Immunomodulation {#sec2.1}
------------------------------------------------------------------------

The four types of dengue vaccine are live attenuated viruses, inactivated viruses, recombinant subunit antigens, and DNA vaccines \[[@r82], [@r124]-[@r129]\]. Compared to vaccines that entail using whole proteins or live attenuated viruses, the advantages of using synthetic peptides vaccines include: i) they contain no infectious agent; ii) lower the biological risk (*e.g.* recombination, reassortment, or genome integration); iii) have less potential for adverse effects (*e.g.* allergenicity or oncogenicity); iv) ease of administration; v) exhibit a high degree of specificity; and vi) are flexible to synthesize \[[@r130], [@r131]\]. Thus, various studies investigating anti-DENV peptides for developing a peptide vaccine are listed in Table **[2](#T2){ref-type="table"}**. In 2009, Amin *et al.* screened a phage-display random peptide library to identify dengue-specific B-cell epitopes \[[@r77]\]. They identified two peptides with sequences similar to specific regions of NS3 and NS4B proteins; the two peptides could be used for developing diagnostic tools or potential vaccines for DENV infection \[[@r77]\]. In 2010, Chakraborty *et al.* adopted a computational approach to locating 19 amino acids in a conserved region of the envelope protein in all four serotypes of DENV, and identified eight overlapping putative cytotoxic T-cell (CTL) epitopes (*i.e.* LGSQEGAMH, AMHTALTGA, EGAMHSALA, GSQEGAMHS, SALAGATEV, SQEGAMHSA, QEGAMHSAL, and GAMHSALAG) within the 19-mer conserved region \[[@r79]\]. They found that a 9-mer AMHTALTGA epitope exhibited the highest affinity with human leukocyte antigen molecules among the eight epitopes \[[@r79]\]. In 2011, Li *et al.* employed bioinformatics approaches and *in vitro* assays to design and synthesize a multi-epitope peptide (P1) containing the DENV-2 envelope domain III as a vaccine. The P1 induced lympho-proliferation *in vitro*, generated CD4^+^ cell immune responses, and inhibited viral replication \[[@r82]\]. In addition, P1 reduced DENV-2 RNA in the blood of mice compared with a control (Day 1: 5.56 ± 3.302 *v.s.* 8.44 ± 6.89, Day 3: 0 *v.s.* 75 ± 24.59, Day 5: 0 *v.s.* 2.86 ± 0.948; unit: ×10^3^ copied/mL) \[[@r82]\]. In 2014, Gil *et al.* used mixtures (protein:DNA = 3:1) of the recombinant capsid protein (C) and ssDNA oligonucleotides from DENV-2 to produce recombinant nucleocapsid-like particles (NLPs-2) as a C-based vaccine that induced a protective CD4^+^ and CD8^+^ cell-mediated immunity in mice without assistance from neutralizing antibodies \[[@r76], [@r78], [@r83], [@r86]\]. In one of three monkeys, NLPs-2 induced interferon-gamma secretion and cytotoxic capacity and reduce the viral load \[[@r86]\]. In 2014, Rocha *et al.* showed that the peptide Pep03, which was derived from the DENV1--4 envelope domain II, induced a humoral response and cytotoxic activity against all DENV serotypes \[[@r88]\]. The viral single ORF polyprotein was post-translationally processed into 10 nonstructural (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) and structural proteins (capsid, premembrane, and envelope), all containing CD8^+^ CTL epitopes \[[@r81]\]. NS3 contains more epitopes (31% of the total) having the most immunogenic effect as compared with the other nine DENV proteins, such as NS5 (22% of the total) \[[@r80], [@r81], [@r84], [@r85]\]. Piazza *et al.* found five NS3 peptide epitopes (three novel and two known) that were recognized by CTL in DENV-infected dendritic cells \[[@r87]\]. In 2015, Luo *et al.* used peptide scanning and a comprehensive bioinformatics analysis to reveal the premembrane protein pr4, which induced high titer antibodies in Balb/c mice \[[@r89]\].

2.2. Development of Peptides Inhibiting DENV Entry {#sec2.2}
--------------------------------------------------

Viral entry, the first stage of the DENV lifecycle, is crucial for the virus to reproduce and thereby establish infection. The E protein is considered a major mediator of viral entry and membrane fusion; thus, considerable efforts have been devoted to developing antiviral agents targeting the E protein \[[@r115], [@r116], [@r146]\]. This section reviews several peptide drug candidates to elucidate research on targeting the E protein (Table **[3](#T3){ref-type="table"}**).

Michael *et al.* investigated viral entry inhibition agents and their application \[[@r91]\]. For example, in 2005, they identified five regions on the E protein with high Wimley--White interfacial hydrophobicity scale scores as potential targets for antiviral peptides. The DN59 peptide, which is related to the stem domain of DENV, inhabited DENV and West Nile virus in a sequence-specific manner. In a study on the LLC-MK2 cell line, the DN59 peptide interfered with viral entry with a 50% inhibitory concentration (IC~50~) in the 10-μM range. DN59 demonstrated \>99% inhibition of plaque formation at concentrations below 25 μM, and no peptide cytotoxicity was observed in concentrations up to 100 mg/mL \[[@r91]\]. In 2010, they applied a computational method to design peptide inhibitors of the E protein. The two peptides with highly inhibitory activity, DN57opt and 1OAN1 (IC~50~ = 8 μm and 7 μm, respectively, in a focus-forming unit assay), hindered virus--host cell binding, interacted with the E protein, and altered the viral surface morphology \[[@r90]\]. In 2011, they evaluated the activity of two anti-DENV entry peptides, DN59 and 1OAN1, as an inhibitor of antibody-dependent enhancement, which can cause severe DENV disease symptoms. An *in vitro* study revealed that the two peptides inhibited infection of FcRII-expressing human K562 cells (IC~50~ = 3 and 6 μm for DN59 and 1OAN1, respectively), and neither peptide was cytotoxic \[[@r92]\]. In 2012, they elaborated on the inhibitory mechanism of peptide DN59; showing that the peptide induces pores in the viral membrane, causing viral RNA leakage. The results showed that DN59 peptide could inhibit all four DENV serotypes at an IC~50~ of 2--5 μM without signs of cytotoxicity to mammalian epithelial and mosquito cells at an IC~50~ of 50 μM \[[@r93]\].

Schmidt *et al.* proposed that peptides derived from the stem region of the E protein in DENV-2 (DV2^419--447^) could inhibit viral infectivity by a two-step mechanism \[[@r94]\]. Initially, DV2^419--447^ bound to a viral membrane was introduced into the cell through endocytosis; leading to subsequent DV2^419--447^ binding to the E protein, and interruption of the conformational rearrangement in the acidic internal environment of the endosome, and consequently blocking the infection \[[@r94]\]. In another study, Schmidt *et al.* further confirmed that Residues^441--447^ mainly interact with the viral membrane and residues^419--440^ bound to the E protein \[[@r95]\]. They also suggested that the potency of stem-derived peptides could be markedly enhanced through appropriate modifications of residues^441--447^ \[[@r95]\].

Alhoot *et al.* employed a bioinformatics algorithm (BioMoDroid) to design peptides targeting domain III of the E protein \[[@r99]\]. The sum of the hydrophobic and charge compatibility indices was calculated, and four peptide candidates were synthesized and investigated. An *in vitro* experiment showed that two peptides, DET2 and DET4, exhibit inhibitory activity against DENV-2 with an IC~50~ \>500 μM and approximately 35 μM, respectively \[[@r99]\]. Laosutthipong *et al.* reported that viprolaxikine, antiviral peptide filtrates from

DENV2 infected mosquito cell cultures, protected both insect and mammalian cells against DENV \[[@r96]\]. Further investigation into viprolaxikine indicated that the antiviral activity derived from three to four strongly anionic heptapeptides (*i.e.* DDHELQD, DETELQD, DEVMLQD and/or DEVLMQD) with the common sequence motif D-D/E-X-X-X-Q-D. The inhibitory activity was attributed to the interaction between viprolaxikine and the host cells, but not to directly acting on DENV2 \[[@r96]\]. Panya *et al.* adopted a molecular-docking method to identify small peptides that specifically bind to the hinge region of the E protein. The inhibitory activity of the seven peptide candidates was tested in Vero cells, and the peptide EF (Glu-Phe) reduced the foci formation by nearly 90% (IC~50~ = 96.5 μM). The results showed that EF inhibited all four DENV serotypes but was most effective against DENV-2 \[[@r97]\]. In 2013, Parikesit *et al.* used the molecular-docking method to screen commercial cyclic peptides in which the possible ligands targeted the E protein. They suggested that porcine BNP(7--32) might be an optimal ligand interacting with the E protein at temperature 310 and 312 K \[[@r98]\].

2.3. Development of Peptides for Anti-DENV Replication {#sec2.3}
------------------------------------------------------

Table **[4](#T4){ref-type="table"}** lists some of the peptides tested for inhibition of DENV replication. NS2B/NS3 is an essential protease for viral replication in host cells \[[@r63]-[@r73]\]. NS2B is a highly conserved nonstructural protein in flaviviruses, acting as a cofactor for NS3 protease activity \[[@r118], [@r120], [@r147], [@r148]\]. In 2005, Li *et al.* identified a suitable substrate for NS2B/NS3 protease by using a tetrapeptide library \[[@r73]\]. Following that study, 2006 Yin *et al.* designed a tetrapeptide inhibitor for reducing the enzyme activity of NS2B/NS3 \[[@r121], [@r149]\]. They tested tetrapeptides with various warheads and found that benzoyl-NKRR-H was the most suitable candidate for inhibiting NS2B/NS3 (*K*~i~ = 5.8 μM) \[[@r121], [@r149]\]. In 2010, Tambunan and Alamudi used a bioinformatics method to design peptide inhibitors for NS2B/NS3 \[[@r71]\]. Seven cyclopentapeptides \[Disulfide Bridge: 1-[@r5]\] were designed (CKRRC, CGRRC, CRGRC, CRTRC, CTRRC, CKRKC, and CRRKC) using a molecular-docking method \[[@r71]\]. The optimal cyclopentapeptide was CKRKC, for which the *K*~i~ was estimated at 0.707 μM \[[@r71]\]. In 2011, Schuller *et al.* modified the benzoyl-KRR-H sequence \[[@r70], [@r149]\] and found that the inhibitory effects of phenylacetyl-KRR-H were more powerful than those of benzoyl-KRR-H (IC~50~ = 6.7 ± 1.1 μM *vs* 127 ± 2.1 μM). Moreover, they found that this new tripeptide was superior to the previously referenced inhibitor benzoyl-NKRR-H with improved IC~50~ value (IC~50~ = 6.7 ± 1.1 μM *vs* 9.5 ± 0.21 μM) \[[@r70]\]. In 2012, they reported the anti-DENV effect of protegin (PG-1), a cationic cyclic peptide \[Disulfide Bridge: 6-15; 8-[@r13]\] isolated from porcine leukocytes \[[@r66]\], finding that the IC~50~ of PG-1 to NS2B/NS3 was 11.7 ± 2.23 μM and the inhibition reached 95.7% at 40 μM \[[@r66]\]. In addition, they demonstrated that PG-1 reduced DENV-2 infection in MK-2 cell lines in a dose-dependent manner and the inhibition reached nearly 100% at 12.5 μM \[[@r66]\]. In 2012, Rothan *et al.* found that retrocyclin-1 (RC-1, Table **[4](#T4){ref-type="table"}**) can act as an anti-DENV peptide containing 18 amino acids \[Disulfide Bridge: 3-16; 5-14; 7-[@r12]\] \[[@r68], [@r122]\]. The RC-1 was θ-defensin with broad-spectrum antimicrobial activity \[[@r150]\]. An *Escherichia coli* expression system and refolding environment for recombinant RC-1 were established, and the recombinant RC-1 was employed to test the inhibitory effect of NS2B/NS3 and DENV-2 infection in Vero cells \[[@r68]\]. The results showed that the IC~50~ of recombinant RC-1 was relative to the temperature (46.1 ± 1.7 μM at 28 °C; 21.4 ± 1.6 μM at 37 °C ; 14.1 ± 1.2 μM at 40 °C), and that the most remarkable reduction in infection rate was achieved when Vero cells were treated simultaneously with recombinant RC-1 (150 μM) and DENV-2 (70% ± 6.3 at 48 h and 85% ± 7.1 at 72 h) compared with pre-treated (40% at 48 h and 38% at 72 h) or post-treated (30% at 48 h and 45% at 72 h) groups \[[@r68]\]. In 2012, Xu *et al.* designed the cyclic peptide CAGKRKSG \[Cyclic bridge:1-[@r8]\] inhibitor against DENV based on MrIA, a conotoxin that can inhibit NS2B/NS3 \[[@r72], [@r123]\]. In 2013, Rothan *et al.* reported that recombinant plectasin peptide could act as an anti-DENV peptide \[[@r69]\]. Plectasin is a 40-amino acid fungal cationic cyclic peptide \[Disulfide Bridge:4-30; 15-37; 19-39 \] produced by *Pseudoplectania nigrella* \[[@r69], [@r151], [@r152]\]. The results showed that the recombinant plectasin inhibited NS2B/NS3 activity (Ki = 5.031 ± 0.98 μM) and enhanced inhibition in a dose-dependent manner (approximately 40% at 5.0 μM; approximately 60% at 10 μM; approximately 80% at 20 μM) \[[@r69]\]. In 2014, Rothan *et al.* reported that latarcin (Ltc 1), the natural antimicrobial agent isolated from spider venom, could inhibit dengue infection *in vitro* \[[@r67]\]. Ltc 1 inhibits NS2B/NS3 activity related to the temperature effect (IC~50~ = 12.68 ± 3.2 μM at 37°C; IC~50~ = 6.58 ± 4.1 μM at 40°C). In addition, peptide against DENV replication assay showed that Ltc 1 treated simultaneously or post-infected HepG2 cells having better inhibitory effects than pre-infected group \[[@r67]\].

Another target for peptide drug design is the NS5 methyltransferase, which has two critical active sites on its surface: a SAM binding site and an RNA-capping site \[[@r74], [@r75]\]. In 2012, Idrus *et al.* employed a molecular-docking methodology to design a peptide inhibitor for NS5 methyltransferase and proposed two cyclic peptides \[Disulfide Bridge: 1-[@r5]\]: CTWYC for the SAM-binding site (Δ*G*~binding~ = -30.72 kcal/mol) and CYEFC for the RNA-capping site (Δ*G*~binding~ = -22.89 kcal/mol) \[[@r74]\]. In 2014, Tambunan *et al.* screened commercial cyclic peptide to inhibit NS5 methyltransferase by molecular dynamics simulation and molecular docking \[[@r75]\]. They suggested that the commercial cyclic peptides \[Tyr[@r123]\] Prepro Endothelin (110-130), amide, human \[Disulfide Bridge: 110-124; 112-[@r120]\]" would bind stably to SAM sites (Δ*G* = -24.73kcal/mol) and "Urotensin II \[Disulfide Bridge: 5--[@r10]\]" would bind stably to RNA-capping sites (Δ*G* = -19.04 kcal/mol).

Conclusion
==========

DENV infection has reemerged as a major public health concern with significant socioeconomic impact resulting in a worldwide changes in prevalence and increase epidemics \[[@r153], [@r154]\]. AVPs and AMPs, a group of evolutionarily conserved small peptides are promising therapeutic candidates for DENV infections because of their known antiviral effects. Three major pathways involved in the DENV lifecycle have been explored as potential targets of peptide-based drugs; immunomodulation, inhibition of viral entry, and interference with specific steps in the viral replication cycle. This review provides a summary of the efforts to develop AVPs for their antiviral and immunogenic capabilities for dealing with DENV infection. Two patented peptides that interfere with DENV entry are currently in development, suggesting that peptide drugs could play a critical role in combating this globally prevalent tropical disease and illustrate the design principles for developing novel drugs as an alternative strategy to overcome microbial drug resistance. Current challenges with AVPs and AMPs reveal that only a few have entered into clinical trials or have been approved by the US Food and Drug Administration (FDA). AVPs and AMPs can be digested by proteolytic enzyme in the gastrointestinal tract following oral administration; short half lives *in vivo*, protease degradation and rapid kidney clearance are limitations for systemic administration \[[@r155]\]. Feasible strategies to circumvent these drawbacks include chemical modification and the use of delivery vehicles \[[@r156], [@r157]\]; therefore, future investigation is warranted to improve their efficacy as well as clinical utility.
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![**The lifecycle of DENV and major strategies for anti-DENV peptide drug development.** The lifecycle of DENV involves complex interactions between viral proteins and host factors. Interaction begins from the E protein contacting the target host cell through receptor-mediated and clathrin-dependent endocytosis \[[@r135]-[@r138]\]. After internalization, viral genomic RNA is released from the endosome because the conformational change in the E protein, which is necessary for membrane fusion to occur, is triggered by pH alteration \[[@r138]-[@r140]\]. A single polyprotein is subsequently translated from the genomic RNA and autocatalytically cleaved into structural and nonstructural proteins through the recruitment of viral NS2B/NS3 and host proteases \[[@r25], [@r141]\]. All processed viral protein subunits are translocated to the endoplasmic reticulum (ER) membrane. Nonstructural proteins are transported to ER-derived vesicular parcels to form a replication complex, while the structural proteins prM and E are embedded into the ER membrane to enclose the nucleocapsid derived from the association of newly synthesized viral RNA with C proteins \[[@r24], [@r139], [@r142]\]. Subsequently, an immature viral particle is generated from the assembly of C, prM, E, and genomic RNA, and then buds into the ER-lumen to enable transport through the secretory pathway. Ultimately, the mature DENV virion is released into the cytoplasm under a low pH through furin-mediated cleavage of prM to M in the trans-Golgi network and can infect the next host cell \[[@r33], [@r141], [@r143]-[@r145]\]. According to the DENV lifecycle, the three major strategies for developing anti-DENV peptide drugs are immunomodulation, anti-DENV entry, and anti-DENV replication \[[@r63]-[@r99]\].](CPPS-19-998_F1){#F1}

###### 

Recent review articles of anti-DENV drugs and vaccines.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pathway**                                                                          **Title**                                                                                                                             **Compounds**                **References**
  ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------
  **Immunomodulation**                                                                 Dengue and soluble mediators of the innate immune system                                                                              Cytokine and antibody        \[[@r106]\]

  Dengue vaccine- priorities and progress                                              Live attenuated, whole-virus vaccine candidates\                                                                                      \[[@r105]\]                  
                                                                                       Live chimeric vaccine candidates\                                                                                                                                  
                                                                                       DNA vaccine\                                                                                                                                                       
                                                                                       Chimeric proteins\                                                                                                                                                 
                                                                                       Recombinant protein                                                                                                                                                

  Next generation dengue vaccines: A review of candidates in preclinical development   Recombinant subunit vaccines\                                                                                                         \[[@r107]\]                  
                                                                                       DNA vaccines\                                                                                                                                                      
                                                                                       Virus Like Particle vaccines\                                                                                                                                      
                                                                                       Virus-vectored vaccines\                                                                                                                                           
                                                                                       Live attenuated virus vaccines\                                                                                                                                    
                                                                                       Heterologous prime-boost approaches                                                                                                                                

  **Pathway**                                                                          **Title**                                                                                                                             **Compounds**                **References**

                                                                                       Targeting host factors to treat West Nile and dengue viral infections                                                                 Small molecule\              \[[@r23]\]
                                                                                                                                                                                                                             Cytokine\                    
                                                                                                                                                                                                                             Antibody\                    
                                                                                                                                                                                                                             Carbohydrate                 

  **Anti-dengue virus entry**                                                          Carbohydrate-related inhibitors of dengue virus entry                                                                                 Carbohydrate                 \[[@r111]\]

  Dengue fever: Natural managemen                                                      Herbal/natural drugs                                                                                                                  \[[@r114]\]                  

  Natural compounds against flaviviral infections                                      Herbal/natural drugs                                                                                                                  \[[@r109]\]                  

  Potential antidengue medicinal plants, a review                                      Herbal/natural drugs                                                                                                                  \[[@r108]\]                  

  Targeting host factors to treat West Nile and dengue viral infections                Small molecule\                                                                                                                       \[[@r23]\]                   
                                                                                       Cytokine\                                                                                                                                                          
                                                                                       Antibody\                                                                                                                                                          
                                                                                       Carbohydrate                                                                                                                                                       

  Ten years of dengue drug discovery- progress and prospects                           Small molecule\                                                                                                                       \[[@r112]\]                  
                                                                                       Peptide                                                                                                                                                            

  Therapeutic antibodies as a treatment option for dengue fever                        Antibody                                                                                                                              \[[@r110]\]                  

  Dengue virus entry as target for antiviral therapy                                   Peptide\                                                                                                                              \[[@r115]\]                  
                                                                                       Small molecule                                                                                                                                                     

  Progress in the identification of dengue virus\                                      Peptide\                                                                                                                              \[[@r116]\]                  
  Entry/Fusion inhibitors                                                              Small molecule                                                                                                                                                     

  Peptides as therapeutic agents for dengue virus                                      Peptide                                                                                                                               \[[@r117]\]                  

  **Anti-dengue virus replication**                                                    A perspective on targeting non-structural proteins to combat neglected tropical diseases- Dengue, West Nile and Chikungunya viruses   Small molecule and peptide   \[[@r113]\]

  Dengue and soluble mediators of the innate immune system                             Cytokine and antibody                                                                                                                 \[[@r106]\]                  

  Dengue fever: Natural management                                                     Herbal/natural drugs                                                                                                                  \[[@r114]\]                  

  Natural compounds against flaviviral infections                                      Herbal/natural drugs                                                                                                                  \[[@r109]\]                  

  Potential antidengue medicinal plants, a review                                      Herbal/natural drugs                                                                                                                  \[[@r108]\]                  

  Targeting host factors to treat West Nile and dengue viral infections                Small molecule\                                                                                                                       \[[@r23]\]                   
                                                                                       Cytokine\                                                                                                                                                          
                                                                                       Antibody\                                                                                                                                                          
                                                                                       Carbohydrate                                                                                                                                                       

  Ten years of dengue drug discovery- progress and prospects                           Small molecule\                                                                                                                       \[[@r112]\]                  
                                                                                       Peptide                                                                                                                                                            

  Peptides as therapeutic agents for dengue virus                                      Peptide                                                                                                                               \[[@r117]\]                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Target and sequence of various peptide vaccines for dengue virus.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Target**     **Peptide sequence**                                                                                    **Origins and Descriptions**                                                                                                              **References**
  -------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  B cell         FERVPGEVT\                                                                                              Two peptides were located in virus nonstructure protein (NS4b and NS3).                                                                   \[[@r77]\]
                 RRALPPVSS                                                                                                                                                                                                                                         

  CD8^+^ cell    AMHTALTGA                                                                                               The synthetic peptide was selected from the 19-mer peptide sequence which is a conserved region in four DENV by computational approach.   \[[@r79]\]

  B cell\        P1:\                                                                                                    The P1 was located in virus-2 E domain III.                                                                                               \[[@r82]\]
  CD4^+^ cell    AKFVAAWTLKAAAGGRHVLGRLITVNPIVTG-GEPGQLNWFKKGSS                                                                                                                                                                                                    

  CD4^+^ cell\   Capsid:\                                                                                                The NLPs-2 consisted of the recombinant capsid protein and ssDNA (ODN M39) (protein:DNA = 3:1).                                           \[[@r76], [@r78], [@r83], [@r86]\]
  CD8^+^ cell    MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPTAGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR\                                                                                                                                             
                 ODN M39:\                                                                                                                                                                                                                                         
                 ATCGACTCTCGAGCGTTCTCGGGGGACGATCGTCGGGGG.                                                                                                                                                                                                          

  B cell\        Pep03:\                                                                                                 The Pep03 was a synthetic peptide that derived from four DENV envelope domain II.                                                         \[[@r88]\]
  CD8^+^ cell    LVTFKTAHAKKQEV-Linker-LVTFKNAAHAKKQEV-Linker-LVTFKNPHAKKQDV-Linker-LVTFKVPHAKRQDV\                                                                                                                                                                
                 Linker:\                                                                                                                                                                                                                                          
                 GGGG                                                                                                                                                                                                                                              

  CD8^+^ cell    NS3~52--60~:\                                                                                           The peptides were synthesized based on NS3 protein.                                                                                       \[[@r87]\]
                 VTRGVY (DENV - 1)\                                                                                                                                                                                                                                
                 VTRGAVLMH (DENV - 2)\                                                                                                                                                                                                                             
                 VTRGAVLTY (DENV - 3·1)\                                                                                                                                                                                                                           
                 VTRGAVLTH (DENV - 3·2)\                                                                                                                                                                                                                           
                 VTRGSV ICH (DENV - 4)\                                                                                                                                                                                                                            
                 NS3~358--368~:\                                                                                                                                                                                                                                   
                 KTVWFVPSIKS (DENV - 1)\                                                                                                                                                                                                                           
                 KTVWFVPSIKA (DENV - 2 - 3 - 4)\                                                                                                                                                                                                                   
                 NS3~501--509~:\                                                                                                                                                                                                                                   
                 TPEGIIPAL (DENV - 1 - 3)\                                                                                                                                                                                                                         
                 TPEGIIPSM (DENV - 2)\                                                                                                                                                                                                                             
                 TPEGIIPTL (DENV - 4)\                                                                                                                                                                                                                             
                 NS3~538--547~:\                                                                                                                                                                                                                                   
                 MRRGDLPVWL (DENV - 1 - 2 - 3 - 4)\                                                                                                                                                                                                                
                 NS3~575--583~:\                                                                                                                                                                                                                                   
                 EENMEVEIW (DENV - 2)\                                                                                                                                                                                                                             
                 EENMDVEIW (DENV - 1 - 3 - 4)                                                                                                                                                                                                                      

  B cell         pr4:\                                                                                                   The pr4 is a short sequence of pre-membrane protein.                                                                                      \[[@r89]\]
                 KGKSLLFKTENGVNMC                                                                                                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Target and sequence of various peptides for anti-DENV entry.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  **Target**                                 **Peptide sequence**                          **Origins and Descriptions**                **References**
  ------------------------------------------ --------------------------------------------- ------------------------------------------- --------------------
  Stem region of E protein                   DN59: MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY       Synthesized                                 \[[@r91]-[@r93]\]

  The domain II hinge                        DN57opt:\                                     Synthesized                                 \[[@r90]\]
                                             RWMVWRHWFHRLRLPYNPGKNKQNQQWP                                                              

  Domain I/domain II beta sheet connection   1OAN1:\                                       Synthesized                                 \[[@r90]\]
                                             FWFTLIKTQAKQPARYRRFC                                                                      

  E protein                                  DV2^419-447^:\                                Synthesized                                 \[[@r94], [@r95]\]
                                             AWDFGSLGGVFTSIGKALHQVFGAIYGAA                                                             

  Domain III of DENV2 E protein              DET2: PWLKPGDLDL\                             Synthesized                                 \[[@r99]\]
                                             DET4: AGVKDGKLDF                                                                          

  Viprolaxikine and host cell                Viprolaxikine:\                               Filtrate from persistently infected cells   \[[@r96]\]
                                             (DDHELQD, DETELQD, DEVMLQD and/or DEVLMQD)\                                               
                                             common motif: D-D/E-X-X-X-Q-D                                                             

  E Protein                                  EF (Glu-Phe)                                  Molecular docking                           \[[@r97]\]

  E Protein                                  BNP(7-32), porcine:\                          Molecular docking                           \[[@r98]\]
                                             DSGCFGRRLDRIGSLSGLGCNVLRRY                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Target and sequence of various peptides for anti-DENV replication.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Target**                                                                          **Peptide sequence**                                                                                                              **Origins and Descriptions**                                                                               **References**
  ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------
  NS2B/NS3                                                                            Benzoyl-NKRR-H                                                                                                                    This peptide was modified from known tetrapeptide substrate benzoyl-NKRR-AMC (7-amido-4-methylcoumarin).   \[[@r64], [@r73], [@r121], [@r149]\]

  CKRKC \[Disulfide Bridge: 1-5\]                                                     This peptide was designed by used molecular docking approach.                                                                     \[[@r71]\]                                                                                                 

  Phenylacetyl-KRR-H                                                                  This peptide was modified from known tri-peptide substrate Bz-KRR-H.                                                              \[[@r70], [@r149]\]                                                                                        

  PG1:\                                                                               PG-1 was isolated form porcine leukocytes.                                                                                        \[[@r66]\]                                                                                                 
  RGGRLCYCRRRFCVCVGR \[Disulfide Bridge: 6-15; 8-13\]                                                                                                                                                                                                                                                                              

  RC-1:\                                                                              RC-1 is encoded in the human genome by a theta-defensins pseudogene.                                                              \[[@r68], [@r122], [@r150]\]                                                                               
  GICRCICGRGICRCICGR \[Disulfide Bridge: 3-16; 5-14; 7-12\]                                                                                                                                                                                                                                                                        

  CAGKRKSG \[Cyclic bridge:1-8\]                                                      This peptide was modified from conotoxins, MrIA, which was produced by cone snail.                                                \[[@r72]\]                                                                                                 

  Plectasin:\                                                                         Plectasin is a fungal peptide produced from *Pseudoplectania nigrella.*                                                           \[[@r69], [@r152]\]                                                                                        
  GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY \[Disulfide Bridge:4-30; 15-37; 19-39 \]                                                                                                                                                                                                                                                

  Ltc 1:\                                                                             Ltc 1 is a peptide from venom gland of *Lachesana tarabaeve*.                                                                     \[[@r67]\]                                                                                                 
  SMWSGMWRRKLKKLRNALKKKLKGE                                                                                                                                                                                                                                                                                                        

  NS5 methyltransferase                                                               CTWYC for SAM binding site \[Disulfide Bridge: 1-5\]\                                                                             These two peptides were designed by used molecular docking approach.                                       \[[@r74]\]
                                                                                      CYEFC for RNA-cap site \[Disulfide Bridge: 1-5\]                                                                                                                                                                                             

  \[Tyr123\] Prepro Endothelin (110-130), amide, human:\                              These two peptides were screen by molecular dynamics simulation and molecular docking approaches from commercial cyclic peptide   \[[@r75]\]                                                                                                 
  CQCASQKDKKWSYCQAGKEI for SAM binding site\                                                                                                                                                                                                                                                                                       
  \[Disulfide Bridge: 110-124; 112-120\]\                                                                                                                                                                                                                                                                                          
  Urotensin II, human\                                                                                                                                                                                                                                                                                                             
  ETPDCFWKYCV for RNA-cap site\                                                                                                                                                                                                                                                                                                    
  \[Disulfide Bridge: 5--10\]                                                                                                                                                                                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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